Toth Financial Advisory Corp reduced its stake in shares of Innoviva Inc (NASDAQ:INVA) by 93.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,000 shares of the biotechnology company’s stock after selling 71,800 shares during the period. Toth Financial Advisory Corp’s holdings in Innoviva were worth $70,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. BlackRock Inc. raised its stake in Innoviva by 2.6% in the 3rd quarter. BlackRock Inc. now owns 11,921,598 shares of the biotechnology company’s stock valued at $181,684,000 after purchasing an additional 304,918 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Innoviva by 12.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,141,849 shares of the biotechnology company’s stock valued at $32,642,000 after purchasing an additional 232,738 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Innoviva by 179.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,026,320 shares of the biotechnology company’s stock valued at $15,641,000 after purchasing an additional 659,372 shares during the last quarter. Deutsche Bank AG raised its stake in Innoviva by 88.6% in the 3rd quarter. Deutsche Bank AG now owns 832,787 shares of the biotechnology company’s stock valued at $12,689,000 after purchasing an additional 391,289 shares during the last quarter. Finally, Jane Street Group LLC raised its stake in Innoviva by 209.8% in the 3rd quarter. Jane Street Group LLC now owns 32,922 shares of the biotechnology company’s stock valued at $502,000 after purchasing an additional 22,296 shares during the last quarter. Institutional investors own 79.09% of the company’s stock.
Shares of INVA stock opened at $13.78 on Wednesday. Innoviva Inc has a twelve month low of $13.26 and a twelve month high of $20.54. The stock has a market capitalization of $1.39 billion, a P/E ratio of 3.90 and a beta of 1.85. The company has a debt-to-equity ratio of 2.41, a current ratio of 34.92 and a quick ratio of 34.92.
Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $2.34 EPS for the quarter. Innoviva had a net margin of 151.36% and a negative return on equity of 508.18%. The company had revenue of $79.86 million during the quarter. On average, analysts expect that Innoviva Inc will post 1.46 EPS for the current year.
In other news, insider Marianne Zhen sold 5,617 shares of the business’s stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $16.00, for a total transaction of $89,872.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Geoffrey Hulme bought 7,000 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were purchased at an average price of $14.80 per share, with a total value of $103,600.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 32,000 shares of company stock valued at $491,100. Corporate insiders own 0.18% of the company’s stock.
Several research analysts recently weighed in on INVA shares. Zacks Investment Research downgraded shares of Innoviva from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. BidaskClub downgraded shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 2nd. Finally, ValuEngine downgraded shares of Innoviva from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $16.00.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Modern Readers and is owned by of Modern Readers. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.modernreaders.com/news/2019/04/17/innoviva-inc-inva-shares-sold-by-toth-financial-advisory-corp.html.
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Further Reading: Trading based on a resistance level
Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.